Show Summary Details
Page of

Human Melanocortin 4 Receptor Deficiency 

Human Melanocortin 4 Receptor Deficiency
Human Melanocortin 4 Receptor Deficiency

I. Sadaf Farooqi

and Stephen O'Rahilly

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 22 April 2021

MC4R deficiency is the commonest monogenic form of obesity. Manipulation of the melanocortin pathway may prove to be a key drug target for obesity. While at present there is no specific therapy for MC4R deficiency, it is highly likely that these patients would respond well to pharmacotherapy that overcame the reduction in the hypothalamic melanocortinergic tone that exists. As most patients are heterozygotes with one functional allele intact, it is possible that small-molecule MC4R agonists might, in future, be appropriate treatments for this disorder.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.